# OnCo record olomorasib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/olomorasib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "olomorasib" ;
  schema:name "Olomorasib"@en ;
  schema:description "Olomorasib is Lilly's KRAS G12C pill, designed to combine safely with immunotherapy in first-line lung cancer."@en ;
  schema:url <https://onco.cc/drugs/olomorasib/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://www.onclive.com/view/olomorasib-plus-pembrolizumab-earns-breakthrough-therapy-designation-in-untreated-kras-g12c-mutated-nsclc> ;
  onco:status "phase-3" ;
  onco:modality "Small-molecule inhibitor (KRAS G12C)" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/kras-g12c-pdac/>, <https://onco.cc/cancers/kras-g12c-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:trials <https://onco.cc/trials/nct04956640/>, <https://onco.cc/trials/nct06119581/>, <https://onco.cc/trials/nct07227025/>, <https://onco.cc/trials/nct06890598/> .